GGrantIndex
← Search

Tumor Environment and Metastasis

$71,173P30FY2025CANIH

Northwestern University At Chicago, Evanston IL

Investigators

Linked publications, trials & patents

Trial NCT07639528Trial NCT07594626Trial NCT07594548Trial NCT07290543Trial NCT07261657Trial NCT07178301Trial NCT07169617Trial NCT07050186Trial NCT07042919Trial NCT06959641Trial NCT06813898Trial NCT06723457Trial NCT06630416Trial NCT06571734Trial NCT06499870Trial NCT06410248Trial NCT06327477Trial NCT06247540Trial NCT06244004Trial NCT06242834Trial NCT06184750Trial NCT06164275Trial NCT06137651Trial NCT06062498Trial NCT06060587Trial NCT06022822Trial NCT05879250Trial NCT05852041Trial NCT05802186Trial NCT05744739Trial NCT05733000Trial NCT05620771Trial NCT05576896Trial NCT05545150Trial NCT05453799Trial NCT05419011Trial NCT05411107Trial NCT05236036Trial NCT05202782Trial NCT05093387Trial NCT04931017Trial NCT04910425Trial NCT04795869Trial NCT04767984Trial NCT04753216Trial NCT04576104Trial NCT04550481Trial NCT04250051Trial NCT04227028Trial NCT04200443Trial NCT04049227Trial NCT04047706Trial NCT04033432Trial NCT04009044Trial NCT03854474Trial NCT03812562Trial NCT03742258Trial NCT03723915Trial NCT03704714Trial NCT03513484Trial NCT03317405Trial NCT03278925Trial NCT03226249Trial NCT03213041Trial NCT03146650Trial NCT03077828Trial NCT03070002Trial NCT03061188Trial NCT03048500Trial NCT03044730Trial NCT03036930Trial NCT03020017Trial NCT02993159Trial NCT02968810Trial NCT02965703Trial NCT02901899Trial NCT02892734Trial NCT02871323Trial NCT02861040Trial NCT02847559Trial NCT02837029Trial NCT02819804Trial NCT02808143Trial NCT02805868Trial NCT02794883Trial NCT02774681Trial NCT02743364Trial NCT02720484Trial NCT02694809Trial NCT02536794Trial NCT02530619Trial NCT02530502Trial NCT02530125Trial NCT02481310Trial NCT02365480Trial NCT02357810Trial NCT02314156Trial NCT02242097Trial NCT02237183Trial NCT02232516

Abstract

ABSTRACT – TUMOR ENVIRONMENT AND METASTASIS The Tumor Environment and Metastasis (TEAM) Program of the Lurie Cancer Center (LCC) is a multidisciplinary basic science program with a focus on cell adhesion, tumor immunology, inflammation, and the lymphovascular system and its role in cancer. TEAM investigators work to elucidate how interactions between tumor cells, immune cells, and components of the host stromal microenvironment mediate tumor development and progression. TEAM Program members address the following three specific aims: (1) Determine how cells interact with each other and their matrix and define how adhesion-mediated cellular events affect tumor cell plasticity, invasion, and metastasis; (2) Elucidate the role of the extracellular matrix and the lymphovascular system in tumor progression and therapeutic resistance; and (3) Understand the role of innate and adaptive immune systems in cancer initiation and progression and develop strategies to effectively activate the immune system against cancer. The TEAM Program has 47 core members from 12 departments and 2 schools at Northwestern University. Program members are highly interactive, collaborating on basic and translational research initiatives. Over the course of the current funding period, program members have published 869 cancer-relevant scientific articles. Of these, 45% were in high-impact journals, 23% were intra-programmatic, and 43% were inter-programmatic. The TEAM Program has $19,054,717 in direct cancer-relevant peer-reviewed funding, with $4,493,058 of this from the NCI and $14,561,659 from other NIH institutes and grant agencies. TEAM members lead multiple projects in large collaborative grants, including two NCI-funded SPORE grants. The three program co-leaders include Hidayatullah Munshi, MD, a physician scientist, with expertise in cell-matrix interactions and matrix-driven drug resistance; Luisa Iruela-Arispe, PhD, whose research work is focused on vascular morphogenesis and the role of lymphovascular system in cancer, and Bin Zhang, MD, PhD, a tumor immunologist with a long-standing interest in developing novel therapies to activate the anti-tumor immune response. Given their complementary expertise, the TEAM leaders are optimally positioned to promote inter- and intra-programmatic interactions and to create interdisciplinary teams that advance TEAM’s basic science discoveries towards clinical translation with a positive impact on the LCC catchment area and community.  

View original record on NIH RePORTER →